NicholasMitsiadesMDPhD
Oncology • Sacramento, CAGenitourinary Oncology
Chief Translational Officer and Associate Director for Translational Research Comprehensive Cancer Center, UC Davis Health and Professor, Department of Internal Medicine, Division of Hematology and Oncology. E-mail: nmitsiades@ucdavis.edu
Dr. Mitsiades is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4501 X Street
Suite 3016
Sacramento, CA 95817Phone+1 916-703-5169- Is this information wrong?
Summary
- Dr. Nicholas Mitsiades is a physician-scientist and clinically-trained medical oncologist and endocrinologist specialized in the treatment of endocrine malignancies, in particular prostate cancer. He is the Chief Translational Officer and Associate Director for Translational Research of the Comprehensive Cancer Center, UC Davis Health. He is a Professor in the Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Health.
E-mail: nmitsiades@ucdavis.edu
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2006 - 2007- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2006
University of AthensClass of 1995
Certifications & Licensure
CA State Medical License 2022 - 2026
TX State Medical License 2010 - 2022
NY State Medical License 2009 - 2011- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member American Society for Clinical Investigation, 2019
Clinical Trials
- S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Start of enrollment: 2011 Aug 09
- Study of Metformin With Simvastatin for Men With Prostate Carcinoma Start of enrollment: 2012 Jan 01
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
- Join now to see all
Publications & Presentations
PubMed
- Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.McMillin, D., Delmore, J., Weisberg, E., Negri, J., Geer, C., Klippel, S., Munshi, N., Mitsiades, C., Mitsiades, N., Schlossman, R., Kung, A., Griffin, J., Richardson,...> ;Nature Medicine. 2024 Feb 14
- 1 citationsEnhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.Kelly, A., Wang, W., Rothenberger, E., Yang, J., Gilligan, M., Kipper, F., Attaya, A., Gartung, A., Hwang, S., Gillespie, M., Bayer, R., Quinlivan, K., Torres, K., Hua...> ;Proceedings of the National Academy of Sciences of the United States of America. 2024 Feb 13
- Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma.Quillan Huang, Irene Mitsiades, Heidi Dowst, Neda Zarrin-Khameh, Attiya Batool Noor, Patricia Castro, Michael E Scheurer, Guilherme Godoy, Martha P Mims, Nicholas Mits...> ;NPJ Precision Oncology. 2023 Nov 18
- Join now to see all
Press Mentions
Cancer Center Appoints New Chief Translational OfficerSeptember 16th, 2022- Tempus Unveils Its Lens Platform, Offering Unparalleled Access to One of the World’s Largest De-Identified Clinical and Molecular DatasetsMay 20th, 2021
Baylor Research Team Gets $6.3M to Study Disparities Among Minorities with Prostate, Breast CancersOctober 22nd, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
